Article
Oncology
Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Summary: The study investigated the relationship between gene expression and treatment benefit of Everolimus in metastatic renal cell carcinoma patients. Specific gene signatures were identified that could potentially predict the response to Everolimus monotherapy or combination therapy with a vascular disrupting agent. Further validation of these gene signatures is needed to determine their clinical utility in patient selection.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amelie Anota, Alicja Puszkiel, Anne Floquet, Helene Vegas, Hugues Bourgeois, Leila Bengrine Lefevre, Benoit You, Fanny Pommeret, Alain Lortholary, Dominique Spaeth, Anne-Claire Hardy-Bessard, Cyril Abdeddaim, Marie-Christine Kaminsky-Forrett, Michel Tod, Jean-Emmanuel Kurtz, Francesco Del Piano, Jerome Meunier, Nadia Raban, Jerome Alexandre, Marie-Ange Mouret-Reynier, Isabelle Ray-Coquard, Magali Provansal Gross, Pierre-Emmanuel Brachet
Summary: In patients with recurrent ovarian cancer progressing during maintenance bevacizumab, the addition of pazopanib to paclitaxel did not improve efficacy, but instead increased toxicity and compromised chemotherapy delivery.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Sonia M. Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg, Timothy J. Hobday, Thomas Semrad, Diane Reidy-Lagunes, Hedy Lee Kindler, George P. Kim, Jennifer J. Knox, Andreas Kaubisch, Miguel Villalona-Calero, Helen Chen, Charles Erlichman, Manisha H. Shah
Summary: This study assessed the efficacy and safety of combining bevacizumab with temsirolimus for advanced extra-pancreatic neuroendocrine tumors. The results showed minimal efficacy and increased side effects with this combination therapy, and it is not recommended for use in these patients.
ENDOCRINE-RELATED CANCER
(2023)
Article
Oncology
Joshua D. Schoenfeld, Narasimhan P. Agaram, Robert A. Lefkowitz, Ciara M. Kelly, John H. Healey, Mrinal M. Gounder
Summary: This article describes the outcomes of five patients with advanced palmar and plantar fibromatosis who were treated with sorafenib. The patients showed objective responses in terms of tumor shrinkage, as well as subjective pain relief and functional improvement. These findings suggest that sorafenib is a well-tolerated and effective oral agent for the treatment of Dupuytren and Ledderhose diseases, and highlight the need for further controlled studies.
Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The retrospective study analyzed clinical data from 343 patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or pazopanib, and found that the use of metformin was associated with significantly longer progression-free survival (PFS) and overall survival (OS) compared to non-users. The Cox multivariate analysis confirmed that metformin use remained a significant factor for both PFS and OS, indicating a favorable outcome for mRCC patients receiving sunitinib or pazopanib treatment.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Kim Westerdijk, Neeltje Steeghs, Casper S. J. Tacke, Winette T. A. van der Graaf, Nielka P. van Erp, Gerard van Oortmerssen, Rosella P. M. G. Hermens, Ingrid M. E. Desar, DPOG
Summary: Personalized dosing based on drug level measurement and adjustment can improve efficacy and reduce toxicity in oncological treatment. However, the use of therapeutic drug monitoring (TDM)-guided dosing for imatinib, sunitinib, and pazopanib is not widely adopted, despite evidence supporting individualized dosing.
Article
Biochemistry & Molecular Biology
Filipa Amaro, Carolina Pisoeiro, Maria Joao Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Marcia Carvalho, Joana Pinto
Summary: This study compared the different cellular and metabolic responses of sunitinib and pazopanib in treating metastatic renal cell carcinoma, suggesting that sunitinib has better in vitro efficacy against target RCC cells and lesser nephrotoxic potential than pazopanib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Physical
Thais Meira Menezes, Antonio Marinho da Silva Neto, Priscila Gubert, Jorge Luiz Neves
Summary: The glycation of HSA under hyperglycemic conditions affects the binding of the drug Pazopanib, potentially impacting drug distribution in antitumoral treatments.
JOURNAL OF MOLECULAR LIQUIDS
(2021)
Article
Oncology
Xiaomi Li, Xiaoyan Ding, Wei Li, Jinglong Chen
Summary: This study suggests that the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) is more effective and well tolerated than mono-TKIs in patients with hepatocellular carcinoma (HCC) who have failed sorafenib (SOR) treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Summary: This study compared the sequential systemic therapy after first-line therapy with sorafenib or lenvatinib and discontinuation of therapy in patients with liver cancer. The results showed that liver functional status and patient performance status at the beginning of first-line therapy had an impact on median overall survival (mOS), while the choice of the initial tyrosine kinase inhibitor (TKI) did not affect mOS.
Article
Hematology
Bibian M. E. Tullemans, Delia Fernandez, Alicia Veninga, Constance C. F. M. J. Baaten, Linsey J. F. Peters, Maureen J. B. Aarts, Johannes A. Eble, Elena Campello, Luca Spiezia, Paolo Simioni, Emiel P. C. van der Vorst, Paola E. J. van der Meijden, Johan W. M. Heemskerk, Marijke J. E. Kuijpers
Summary: Sunitinib inhibits collagen-induced procoagulant activity and delays fibrin formation, which is exacerbated by aspirin. Therefore, we urge awareness of the combined antiplatelet effects of TKIs with aspirin, as this may lead to an increased risk of bleeding.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Biochemistry & Molecular Biology
Robin Frobom, Erik Berglund, Craig A. Aspinwall, Weng-Onn Lui, Inga-Lena Nilsson, Catharina Larsson, Robert Branstrom
Summary: The study investigated the effects of three clinically established TKIs (imatinib, sunitinib, nilotinib) on KATP channel activity, revealing that these drugs can decrease KATP channel activity by interacting with the ATP-binding site on the channel. This interaction may contribute to some of the side effects associated with TKIs.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K. -H. Chun, Roman A. Blaheta
Summary: Axitinib significantly suppressed the growth of sunitinib-resistant HUVECs and induced cell cycle arrest at the G0/G1 phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure in sunitinib-resistant HUVECs after six weeks of treatment, with sorafenib showing slightly better results.
Review
Chemistry, Analytical
Asmaa M. AboulMagd, Nada S. Abdelwahab
Summary: This review discusses the characteristics and analytical methods for determination of sunitinib malate, emphasizing the need for alternative methods that are cost-effective, require minimal sample preparation, consume less toxic solvents, and leave minimal residue. The literature also reveals a lack of research on potential drug-drug pharmacokinetic interactions.
MICROCHEMICAL JOURNAL
(2021)
Article
Urology & Nephrology
Robert J. Motzer, Paul Russo, Naomi Haas, Christian Doehn, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae Lyun Lee, Ho Yeong Lim, Bohuslav Melichar, Milada Zemanova, Brian Rini, Toni K. Choueirim, Lori Wood, M. Neil Reaume, Arnulf Stenzl, Simon Chowdhury, Ray McDermott, Agnieszka Michael, Miguel Izquierdo, Paola Aimone, Hong Zhang, Cora N. Sternberg
Summary: The PROTECT study found no significant difference in overall survival for patients with locally advanced RCC at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo, indicating that pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC.
Article
Oncology
Roberto Iacovelli, Chiara Ciccarese, Orazio Caffo, Ugo De Giorgi, Umberto Basso, Marcello Tucci, Claudia Mosillo, Marco Maruzzo, Francesca Maines, Chiara Casadei, Michele Milella, Giampaolo Tortora
Summary: This study assessed the prognostic role of PSA response in castration-sensitive prostate cancer (CSPC) patients and found that a deep and fast PSA response correlated with a better outcome. Furthermore, the study revealed that achieving a PSA response within 4 months can influence the treatment outcomes of subsequent castration-resistant disease (CRPC).
ANTICANCER RESEARCH
(2022)
Review
Immunology
Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Ilaria Esposito, Anna Acampora, Jacopo Romagnoli, Alessandro Di Stefani, Laura Del Regno, Valentina Lancellotta, Bruno Fionda, Luca Tagliaferri, Ketty Peris, Giampaolo Tortora
Summary: Kidney transplant recipients with melanoma who use anti-PD1 and anti-CTLA4 agents may experience graft rejections, but the response rates are similar between patients with rejection and without. The benefits of immune-checkpoint inhibitors versus the risk of rejection should be carefully considered and a multidisciplinary approach should be taken to discuss the most appropriate treatment for each patient.
Article
Oncology
Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh, Anke Reinacher-Schick, Giampaolo Tortora, Hana Alguel, Eileen M. O'Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan
Summary: The POLO study demonstrated that active olaparib maintenance therapy did not show a statistically significant overall survival benefit for patients with metastatic pancreatic adenocarcinoma, but did show significant benefits in other secondary endpoints.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Alexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, Ulrich Schratzenstaller, Miklos Pless, Marcus Hentrich, Susanne Krege, Anja Lorch, Daniel -M Aebersold, Paul Martin Putora, Dominik-R Berthold, Deborah Zihler, Friedemann Zengerling, Annette Dieing, Arndt -Christian Mueller, Corinne Schaer, Christine Biaggi, Silke Gillessen, Richard Cathomas
Summary: A novel approach combining de-escalated chemotherapy with de-escalated involved node radiotherapy resulted in a 3-year progression-free survival rate of 93.7% with minimal toxic effects. The primary endpoint was not met, but the findings suggest that this regimen could be an alternative to standard-of-care treatment. Further research is needed to confirm these results.
Article
Oncology
Elizabeth J. Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, Maria Vieito, Rowan E. Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert
Summary: INCAGN01949, a fully human anti-OX40 agonist monoclonal antibody, showed no safety concerns as monotherapy in patients with advanced solid tumors, but limited tumor responses and pharmacodynamic effects on T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol, Rubina Novelli, Marcello Allegretti, Andrea Aramini, Alessia Caggiano, Alessia Granitto, Francesco De Sanctis, Stefano Ugel, Vincenzo Corbo, Maurizio Martini, Rita Teresa Lawlor, Aldo Scarpa, Giampaolo Tortora
Summary: This study evaluated the effectiveness of combining a CXCR1/2 inhibitor with anti-PD-1 in treating immunosuppression in PDAC. The results showed that this combination therapy can reverse M2 macrophage polarization, reduce tumor burden, and improve the efficacy of immunotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Mariacristina Di Marco, Guido Giordano, Enrico Vasile, Mario Scartozzi, Silvia Bozzarelli, Silvia Noventa, Maria Grazia Rodriquenz, Anna Maria Militello, Ilario Giovanni Rapposelli, Ingrid Garajova, Stefania De Lorenzo, Barbara Merelli, Alessandro Bittoni, Lisa Salvatore, Letizia Procaccio, Chiara Paratore, Andrea Spallanzani, Umberto Peretti, Monica Niger, Elisa Giommoni, Ilaria Bernardini, Emiliano Tamburini, Katia Bernardino, Laura Forti, Maria Maddalena Valente, Stefano Cascinu, Michele Milella, Michele Reni
Summary: This study demonstrates the beneficial role of platinum agents in PDAC patients with gBRCA1-2pv, both in second-line treatment and as part of early 3- and 4-drug platinum-based chemotherapy combinations, providing improved survival outcomes.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Ilaria Trestini, Alberto Caldart, Marco Cintoni, Isabella Sperduti, Alessandro Drudi, Gregorio Aluffi, Elena Fiorio, Veronica Parolin, Valentina Zambonin, Sara Zanelli, Daniela Tregnago, Alice Avancini, Sara Pilotto, Irene Aprili, Emanuela Zandona, Mirko D'Onofrio, Maria Cristina Mele, Antonio Gasbarrini, Giovanni Scambia, Giampaolo Tortora, Michele Milella, Emilio Bria, Luisa Carbognin
Summary: This study evaluated the changes in body composition during neoadjuvant chemotherapy and its association with pathologic complete response and survival outcome in patients treated for operable locally advanced breast cancer.
Correction
Multidisciplinary Sciences
Marek Cmero, Ke Yuan, Cheng Soon Ong, Jan Schroeder, Niall M. Corcoran, Tony Papenfuss, Christopher M. Hovens, Florian Markowetz, Geoff Macintyre
NATURE COMMUNICATIONS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Minna Cloitre, Massimo Valerio, Ange Mampuya, Arnas Rakauskas, Dominik Berthold, Thomas Tawadros, Jean-yves Meuwly, Leonie Heym, Frederic Duclos, Veronique Vallet, Michele Zeverino, Patrice Jichlinski, John Prior, Beat Roth, Jean Bourhis, Fernanda G. Herrera
Summary: The study aimed to investigate the safety, impact on quality of life, and preservation of local control in patients with intermediate-high risk prostate cancer receiving stereotactic dose escalation using a rectal balloon spacer. The results showed that the treatment was safe and did not negatively affect patient quality of life, while effectively controlling the disease locally.
BRITISH JOURNAL OF RADIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Oncology
Valeria Interno, Maria Chiara Sergi, Maria Elvira Metta, Michele Guida, Paolo Trerotoli, Sabino Strippoli, Salvatore Circelli, Camillo Porta, Marco Tucci
Summary: This study retrospectively analyzed the impact of clinical-pathological features and multimodal therapies on the overall survival of patients with melanoma brain metastases. The results showed that encephalic radiotherapy significantly improved survival, but not for patients with LDH levels higher than two times the upper limit normal. These findings can help guide therapeutic strategies for patients in the worst prognostic subgroup of melanoma brain metastases.
Article
Oncology
Gerhardt Attard, Laura Murphy, Noel W. Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L. Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J. Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H. Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: This study analyzed two open-label, randomized, controlled phase 3 trials and evaluated the long-term outcomes and survival benefits of combining abiraterone and enzalutamide with androgen deprivation therapy in metastatic prostate cancer patients. The results showed that the combination of abiraterone and enzalutamide did not improve survival compared to androgen deprivation therapy alone, but the addition of abiraterone to androgen deprivation therapy had clinically significant improvements in survival.
Review
Medicine, General & Internal
Arnoud J. Templeton, Aurelius Omlin, Dominik Berthold, Joerg Beyer, Irene A. Burger, Daniel Eberli, Daniel Engeleri, Christian Fankhauser, Stefanie Fischer, Silke Gillessen, Guillaume Nicolas, Stephanie Kroeze, Anja Lorch, Michael Muentener, Alexandros Papachristofilou, Niklaus Schaefer, Daniel Seiler, Frank Stenner, Petros Tsantoulis, Tatjana Vlajnic, Thomas Zilli, Daniel Zwahlen, Richard Cathomas
Summary: The management of prostate cancer is rapidly changing, with new diagnostic tools and evolving treatment options. To improve disease management and patient outcomes, a Swiss consensus meeting was held to develop a national consensus on the use of these novel strategies.
SWISS MEDICAL WEEKLY
(2023)